Table 2.
Dose Titration During the Open-Label Period; Adjustments by Weeka
| Titration of MPH ERCT during OL period | ||||
|---|---|---|---|---|
| OL week | Increased n (%) | Decreased n (%) | Maintained n (%) | Total n |
| 1 | 72 (80.0) | 0 | 18 (20.0) | 90 |
| 2 | 64 (71.9) | 0 | 25 (28.1) | 89 |
| 3 | 31 (35.2) | 2 (2.3) | 55 (62.5) | 88 |
| 4 | 18 (20.7) | 5 (5.7) | 64 (73.6) | 87 |
| 5 | 3 (3.5) | 2 (2.3) | 81 (94.2) | 86 |
| 6 | 0 | 0 | 85 (100) | 85 |
a
Dose adjustments were made following efficacy assessment; adjustment was not allowed at the week 6 visit.
MPH ERCT, methylphenidate extended-release chewable tablets; OL, open label.